Mihailović, Jasna

Link to this page

Authority KeyName Variants
1c28357a-b3a5-43fc-9c8d-ef3c1fcfff71
  • Mihailović, Jasna (1)
Projects

Author's Bibliography

Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer

Stanković, Aljoša; Mihailović, Jasna; Mirković, Marija D.; Radović, Magdalena; Milanović, Zorana; Ognjanović, Miloš; Janković, Drina; Antić, Bratislav; Mijović, Milica; Vranješ-Đurić, Sanja; Prijović, Željko

(2020)

TY  - JOUR
AU  - Stanković, Aljoša
AU  - Mihailović, Jasna
AU  - Mirković, Marija D.
AU  - Radović, Magdalena
AU  - Milanović, Zorana
AU  - Ognjanović, Miloš
AU  - Janković, Drina
AU  - Antić, Bratislav
AU  - Mijović, Milica
AU  - Vranješ-Đurić, Sanja
AU  - Prijović, Željko
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9117
AB  - Combined radionuclide therapy with magnetic nanoparticles-mediated hyperthermia has been under research focus as a promising tumor therapy approach. The objective of this study was to investigate the potential of 131I-radiolabeled superparamagnetic iron oxide nanoparticles (SPIONs) prepared as the ~40 nm flower-shaped structures with excellent heating efficiency (specific absorption rate at H0 = 15.9 kA∙m−1 and resonant frequency of 252 kHz was 123.1 W∙g−1) for nano-brachytherapy of tumors. 131I-radiolabeled CC49 antibody attached to SPIONs via reactive groups of 3-aminopropyltriethoxysilane (APTES) provided specificity and long-lasting localized retention after their intratumoral application into LS174T human colon adenocarcinoma xenografts in NOD-SCID mice. The results demonstrate feasibility and effectiveness of magnetic hyperthermia (HT), radionuclide therapy (RT) and their combination (HT + RT) in treating cancer in xenograft models. Combined therapy approach induced a significant (p < 0.01) tumor growth suppression in comparison to untreated groups presented by the tumor volume inhibitory rate (TVIR): 54.38%, 68.77%, 73.00% for HT, RT and HT + RT, respectively in comparison to untreated group and 48.31%, 64,62% and 69,41%, respectively, for the SPIONs-only injected group. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity. Obtained data support the idea that nano-brachytherapy combined with hyperthermia is a promising approach for effective cancer treatment.
T2  - International Journal of Pharmaceutics
T1  - Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer
VL  - 587
SP  - 119628
DO  - 10.1016/j.ijpharm.2020.119628
ER  - 
@article{
author = "Stanković, Aljoša and Mihailović, Jasna and Mirković, Marija D. and Radović, Magdalena and Milanović, Zorana and Ognjanović, Miloš and Janković, Drina and Antić, Bratislav and Mijović, Milica and Vranješ-Đurić, Sanja and Prijović, Željko",
year = "2020",
abstract = "Combined radionuclide therapy with magnetic nanoparticles-mediated hyperthermia has been under research focus as a promising tumor therapy approach. The objective of this study was to investigate the potential of 131I-radiolabeled superparamagnetic iron oxide nanoparticles (SPIONs) prepared as the ~40 nm flower-shaped structures with excellent heating efficiency (specific absorption rate at H0 = 15.9 kA∙m−1 and resonant frequency of 252 kHz was 123.1 W∙g−1) for nano-brachytherapy of tumors. 131I-radiolabeled CC49 antibody attached to SPIONs via reactive groups of 3-aminopropyltriethoxysilane (APTES) provided specificity and long-lasting localized retention after their intratumoral application into LS174T human colon adenocarcinoma xenografts in NOD-SCID mice. The results demonstrate feasibility and effectiveness of magnetic hyperthermia (HT), radionuclide therapy (RT) and their combination (HT + RT) in treating cancer in xenograft models. Combined therapy approach induced a significant (p < 0.01) tumor growth suppression in comparison to untreated groups presented by the tumor volume inhibitory rate (TVIR): 54.38%, 68.77%, 73.00% for HT, RT and HT + RT, respectively in comparison to untreated group and 48.31%, 64,62% and 69,41%, respectively, for the SPIONs-only injected group. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity. Obtained data support the idea that nano-brachytherapy combined with hyperthermia is a promising approach for effective cancer treatment.",
journal = "International Journal of Pharmaceutics",
title = "Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer",
volume = "587",
pages = "119628",
doi = "10.1016/j.ijpharm.2020.119628"
}
Stanković, A., Mihailović, J., Mirković, M. D., Radović, M., Milanović, Z., Ognjanović, M., Janković, D., Antić, B., Mijović, M., Vranješ-Đurić, S.,& Prijović, Ž.. (2020). Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer. in International Journal of Pharmaceutics, 587, 119628.
https://doi.org/10.1016/j.ijpharm.2020.119628
Stanković A, Mihailović J, Mirković MD, Radović M, Milanović Z, Ognjanović M, Janković D, Antić B, Mijović M, Vranješ-Đurić S, Prijović Ž. Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer. in International Journal of Pharmaceutics. 2020;587:119628.
doi:10.1016/j.ijpharm.2020.119628 .
Stanković, Aljoša, Mihailović, Jasna, Mirković, Marija D., Radović, Magdalena, Milanović, Zorana, Ognjanović, Miloš, Janković, Drina, Antić, Bratislav, Mijović, Milica, Vranješ-Đurić, Sanja, Prijović, Željko, "Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer" in International Journal of Pharmaceutics, 587 (2020):119628,
https://doi.org/10.1016/j.ijpharm.2020.119628 . .
20
6
17